Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

Abstract: Embodiments of the present invention comprise computer-based tools facilitating visualization and assessment of progression of neurological disorders in a patient. In one embodiment, data is received in the form of the results of standardized neurological examination of the patient. This input is compared to a rule set defining progression of the disorder, and the results of this comparison are displayed in an electronic document featuring internal links. The data may be displayed as tables and/or charts, with elapsed time plotted along a row/column or axis, respectively. Progression indication may be displayed through changed color. The electronic document can also display data not directly relevant to neurological condition, for example medication and radiation treatment schedules. By automatically displaying the data and the derived progression assessment according to the rule set, embodiments of the present invention are of particularly use in rapidly and uniformly evaluating treatment therapies.